Results 41 to 50 of about 7,079 (166)

GRIA2 Variant Associated With Paradoxical Response to Perampanel Expanding the Spectrum of GRIA2‐Related Epileptic Encephalopathy: Case Report and Literature Review

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction GRIA2 encodes the GluA2 ionotropic α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor subunit. Pathogenic GRIA2 variants cause epilepsy, developmental delay, and neurobehavioral disorders. Characterizations of clinical features, including seizure types and their treatments, in patients with GRIA2‐related ...
Sai Srihitha Dommata, Chhitij Tiwari, Zheng Fan, Muge Gucsavas‐Calikoglu, Yael Shiloh‐Malawsky, Kimberly S. Foss, Stephanie N. Peck, Erin L. Heinzen, Chon Lee, Senyene E. Hunter   +9 more
wiley   +1 more source

Vigabatrin treatment in children

, 1994
Sixty-nine children, aged from 2 months to 16 years and suffering from different types of drug-resistant epileptic seizures, mostly complex partial and secondary generalised, were recruited in an open, uncontrolled, prospective study of treatment with ...
FOIS, A., DI MARCO, V., MOSTARDINI, R., DI BARTOLO, R., BUONI, S.   +4 more
core   +1 more source

The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid [PDF]

, 2006
SummaryPurposeData on the blood pharmacokinetics of vigabatrin, an antiepileptic drug with a unique and novel mechanism of action, in the rat are sparse. Additionally, little is known of the kinetics of vigabatrin in the central cerebrospinal fluid (CSF)
X. Tong, Ratnaraj, N., Tong, X., N. Ratnaraj, P.N. Patsalos, Patsalos, P.N.   +5 more
core   +1 more source

The effectiveness of adding on or switching antiseizure medications after the first fails to control focal epilepsy: A systematic review of randomized controlled trials

Epileptic Disorders, EarlyView.
Abstract Focal epilepsy constitutes 60–70% of epilepsy, and up to half of patients do not achieve seizure freedom with their first antiseizure medication (ASM). When the first ASM fails, evidence guiding whether to switch or add‐on another ASM and which ASMs to use is limited. This review synthesized evidence from randomized controlled trials (RCTs) on
Isaac J. Egesa, Gashirai Mbizvo, Michelle Maden, Thomas Spain, Richard Emsley, Laura J. Bonnett, Anthony G. Marson, Catrin Tudur Smith   +7 more
wiley   +1 more source

The effect of antiseizure medications on the exposure to combined oral contraceptives: A systematic review and network meta‐analysis

Epileptic Disorders, EarlyView.
Abstract Objective Current recommendations for prescribing combined oral contraceptives (COCs) to people with epilepsy are often conflicting, particularly for weak inducers of cytochrome P450 3A4. We aimed to critically review the literature and compare the antiseizure medication (ASM)‐induced changes in exposure to COC components.
Hagar Cohen, Amnah Omar Mahajna, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +4 more
wiley   +1 more source

Response to anti-seizure medications in children carrying novel or previously reported HCN1 gene variants. [PDF]

Epilepsia Open
Abstract Objective Variants in the HCN1 gene cause a syndrome of childhood epilepsy and developmental disability with a broad phenotypic range. Many affected children manifest with early infantile epileptic encephalopathy (EIEE) and highly drug‐resistant epilepsy.
Khan MN, Poolos NP.
europepmc   +2 more sources

Risk of hostility and aggression with perampanel monotherapy versus combination therapy in pediatric epilepsy: A Japanese post‐marketing database study using a nested case–control design

Epileptic Disorders, EarlyView.
Abstract Objective To compare the incidence of hostility‐ and aggression‐related adverse events in children with focal‐onset seizures (FOS), with or without focal to bilateral tonic–clonic seizures (FBTCS), receiving perampanel as monotherapy or in combination with other antiseizure medications (ASMs).
Yukitoshi Takahashi, Masato Takeuchi, Akiko Yoshimura, Kasumi Daidoji, Kazuhiro Matsutani, Mika Ishii   +5 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

New onset refractory status epilepticus (NORSE) versus refractory status epilepticus not meeting NORSE criteria: A comparative clinical and electroencephalography‐based study

Epilepsia, EarlyView.
Abstract Objective New onset refractory status epilepticus (NORSE) is a rare, severe presentation of refractory status epilepticus (RSE), with approximately half of cases cryptogenic NORSE (c‐NORSE). We compared electroencephalographic (EEG) findings alongside clinical features between NORSE and RSE not meeting NORSE criteria to better understand ...
Seren Hawksworth, Nina Moutonnet, Gregory Scott, Sanjeev Rajakulendran, Mahinda Yogarajah, Matthew C. Walker, Umesh Vivekananda   +6 more
wiley   +1 more source

Vigabatrin-Induced Encephalopathy in a 5.5-Month-Old Girl with Infantile Spasms due to Tuberous Sclerosis

Case Reports in Pediatrics, 2019
A 5.5-month-old female infant with tuberous sclerosis complex presented with infantile spasms and was treated with vigabatrin. As her condition did not improve, she was given adrenocorticotropic hormone (ACTH) intramuscularly which stopped the spasms and
Eleni Klinaki, Ioanna Argyri, Georgia Amountza, Gerina Ioannidou, Despoina Maritsi, Anastasia Garoufi, George Vartzelis   +6 more
doaj   +1 more source